Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2- based immunotherapy

Cancer Journal from Scientific American

Volumn 4, Issue 2, 1998, Pages 86-93

  Lee, David S ^a   White, Donald E ^a   Hurst, Ronald ^a   Rosenberg, Steven A ^a   Yang, James C ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Immunotherapy; Interleukin 2; Melanoma; Metastasectomy; Relapse; Renal cell cancer

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2; MACROGOL; TUMOR NECROSIS FACTOR;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL PROTOCOL; DRUG MEGADOSE; DRUG RESPONSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR ASSOCIATED LEUKOCYTE;

CARCINOMA, RENAL CELL; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; NEOPLASM RECURRENCE, LOCAL; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032462716     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Rosenberg SA, Lotze MT, Yang JC et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-483.
2. Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymphokine-activaced killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-1492.
3. Rosenberg SA, Packard BS, Abersold PM et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988;319: 1676-1680.
4. Topalian SL, Muul LM, Solomon D et al. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 1987;102:127-141.
5. Rosenberg SA, Lotze MT, Yang JC et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989;12:1863-1874.
6. Yang JC, Topalian SL, Schwartzentruber DJ et al. The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. Cancer 1995;76:687-694.
7. Yang JC, Topalian SL, Parkinson D et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 1994;12:1572-1576.
8. Sleijfer DT, Janssen RA, Buter J et al. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 1992;10:1119-1123.
9. Mule JJ, Asher A, McIntosh J et al. Antitumor effect of recombinant tumor necrosis factor-α against murine sarcomas at visceral sites: tumor size influences the response to therapy. Cancer Immunol Immunother 1988;26:202-208.
10. 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996;88:100-108.
11. Rosenberg SA, Kawakami Y, Robbins PF et al. Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. Adv Cancer Res 1996;70:145-177.
12. Critchfield JM, Racke MK, Zuniga-Pflucker JC et al. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 1994;263:1139-1143.
13. Ju ST, Panka DJ, Cui H et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995;373:444-448.
14. Hahne M, Rimoldi D, Schroter M et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996;274:1363-1366.